Industry
Biotechnology
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Loading...
Open
6.74
Mkt cap
150M
Volume
369K
High
6.74
P/E Ratio
-1.05
52-wk high
12.85
Low
6.20
Div yield
N/A
52-wk low
4.61
Portfolio Pulse from
November 06, 2024 | 1:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 3:25 pm
Portfolio Pulse from Benzinga Insights
October 03, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 12:40 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 10:16 am
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:52 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:13 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 2:27 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.